Physician profile
Jeffrey Stone
NPI 1154410538
$7,383.93
in general payments reported to CMS, 2019-2025
39 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,815 · 2020: $1,399 · 2021: $1,269 · 2022: $1,077 · 2023: $825 · 2024: $625 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,012.15 | 2019-2025 | Ozempic, Rybelsus, Fiasp |
| Amgen INC. | $916.90 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $611.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $529.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $497.52 | 2019-2024 | Vraylar, Synthroid |
| Pfizer INC. | $349.06 | 2019-2025 | |
| Amarin Pharma, INC. | $334.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.83 | 2019-2023 | |
| Lilly USA, LLC | $318.38 | 2019-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $250.96 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $241.79 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $237.90 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.41 | 2019-2022 | |
| Abbott Laboratories | $232.06 | 2019-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $150.20 | 2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.